Sotera Health reaffirms 2022 guidance, plans $425M Term Loan B to fund $408M EO litigation settlement

Sotera Health Co

Reaffirms 2022 net revenue guidance of $995M-$1.005B and Adjusted EBITDA of $500M-$510M.
Expects 2022 net loss of $226M-$236M including a $408M legal reserve for ethylene oxide settlement.
Plans $425M Term Loan B facility to fund $408M EO settlement, pay down revolver, and boost liquidity.
Preliminary estimates subject to completion of year-end closing; final results expected February 28, 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Sotera Health Co reported the year ended December 31, 2022 results: revenue $995 million to $1.005 billion, net income $226 million to $236 million. Guidance reaffirmed.

Period: the year ended December 31, 2022
Revenue: $995 million to $1.005 billion
Net income: $226 million to $236 million
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

The Company is reaffirming its expectation that 2022 full-year net revenues will be within the previously announced guidance range of $995 million to $1.005 billion. The Company also is announcing that the 2022 full-year net loss is expected to be in a range of $226 million to $236 million

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Sotera Health Co filing history →

Source: SEC EDGAR

accession 0001193125-23-034187

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.